249 related articles for article (PubMed ID: 6092320)
1. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E
J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320
[TBL] [Abstract][Full Text] [Related]
2. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
4. Baculovirus replication: inhibition of Trichoplusia ni multiple nuclear polyhedrosis virus by [E]-5-(2-bromovinyl)-2'-deoxyuridine.
Wang X; Lescott T; De Clercq E; Kelly DC
J Gen Virol; 1983 Jun; 64 (Pt 6)():1221-7. PubMed ID: 6343553
[TBL] [Abstract][Full Text] [Related]
5. 5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
Wigerinck P; Pannecouque C; Snoeck R; Claes P; De Clercq E; Herdewijn P
J Med Chem; 1991 Aug; 34(8):2383-9. PubMed ID: 1652017
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs.
De Clercq E; Walker RT
Pharmacol Ther; 1984; 26(1):1-44. PubMed ID: 6099893
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E; Descamps J; Balzarini J; Fukui T; Allaudeen HS
Biochem J; 1983 May; 211(2):439-45. PubMed ID: 6307280
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.
Andrei G; Snoeck R; Neyts J; Sandvold ML; Myhren F; De Clercq E
Antiviral Res; 2000 Mar; 45(3):157-67. PubMed ID: 10771080
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Harris SA; McGuigan C; Andrei G; Snoeck R; De Clercq E; Balzarini J
Antivir Chem Chemother; 2001 Sep; 12(5):293-300. PubMed ID: 11900348
[TBL] [Abstract][Full Text] [Related]
11. Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.
Swierkosz EM; Arens MQ; Rivetna KA
J Clin Microbiol; 1985 Mar; 21(3):459-61. PubMed ID: 2984249
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses.
Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P
Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459
[TBL] [Abstract][Full Text] [Related]
14. The development of BVDU: An odyssey.
De Clercq E
Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells.
Balzarini J; De Clercq E
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):379-89. PubMed ID: 2545982
[No Abstract] [Full Text] [Related]
16. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8.
Tomicic MT; Friedrichs C; Christmann M; Wutzler P; Thust R; Kaina B
Mol Pharmacol; 2003 Feb; 63(2):439-49. PubMed ID: 12527816
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus type 1 that exhibits herpes simplex virus type 2 sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Docherty JJ; Dobson AT; Trimble JJ; Jennings BA
Intervirology; 1991; 32(5):308-15. PubMed ID: 1657822
[TBL] [Abstract][Full Text] [Related]
19. Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus.
Weber O
Antivir Chem Chemother; 2000 Jul; 11(4):283-90. PubMed ID: 10950390
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
De Clercq E; Desgranges C; Herdewijn P; Sim IS; Jones AS; McLean MJ; Walker RT
J Med Chem; 1986 Feb; 29(2):213-7. PubMed ID: 3005566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
